biotech / news / / MarketScreener
Swiss pharmaceutical giant Roche said on Thursday it had agreed to acquire U.S.-based digital pathology and AI-powered technology firm PathAI.
Roche will acquire PathAI for $750 million upfront plus up to $300 million in milestone payments.
KEY POINTS
- PathAI will become part of Roche's diagnostics division after the deal closes in the second half of 2026.
- The acquisition follows a partnership expanded in 2024 to co-develop AI-enabled companion diagnostic algorithms.
- Roche aims to use PathAI to fully automate digital pathology workflows with advanced AI technology.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →